Skip to main content
. 2015 Aug 10;112(34):10786–10791. doi: 10.1073/pnas.1422749112

Fig. S1.

Fig. S1.

Treatment with mAb81.2 reduces the leukemic burden in the MA9Ras xenotransplantation model. (A) MA9Ras cell engraftment in BM and spleen of unconditioned NOD/SCID mice without antibody treatment (means ± SD; n = 9). (B) Spleen weight in mice engrafted with MA9Ras and treated with mAb81.2 or isotype control (means ± SD; n = 7 in both groups). (C) H&E-stained and human CD45-immunostained spleen sections from representative control and mAb81.2-treated mice. (Scale bars, 300 μm.) P values were calculated with Student’s t test.